United Kingdom

Freeline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Phase 1/2 Gene Therapy Biotech Freeline Therapeutics Files for a $100 million US IPO

Lead Product(s): FLT180a

Therapeutic Area: Genetic Disease Product Name: FLT180a

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering July 17, 2020

Details:

The company's lead candidate, FLT180a, an investigational gene therapy medicinal product candidate for the treatment of hemophilia B, is currently in a Phase 1/2 trial and has dosed 10 patients as of June 15, 2020.

Freeline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Freeline Closes Major $120M Funding Round

Lead Product(s): FLT180a

Therapeutic Area: Genetic Disease Product Name: FLT180a

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Novo Holdings

Deal Size: $120.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing June 30, 2020

Details:

Freeline expects to use the proceeds from the financing to bring its lead program in Haemophilia B into a pivotal trial, as well as to continue its Phase 1/2 clinical program for Fabry Disease and further progress its pipeline programs for Gaucher Disease and Haemophilia A.

Freeline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Freeline Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Lead Product(s): FLT180a

Therapeutic Area: Genetic Disease Product Name: FLT180a

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients.

Orchard Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Orchard Therapeutics Unveils New Strategic Plan

Lead Product(s): OTL-101

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

Orchard Therapeutics to establish OTL-200, OTL-103, OTL-203 and OTL-201 programs as top near-term priorities and reduce investment in OTL-101and OTL-300.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Freeline

Phase 1/2 Gene Therapy Biotech Freeline Therapeutics Files for a $100 million US IPO

Freeline

Freeline Closes Major $120M Funding Round

Freeline

Freeline Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Orchard Therapeutics

Orchard Therapeutics Unveils New Strategic Plan